RELATED PARTY TRANSACTIONS |
9 Months Ended | |
|---|---|---|
Sep. 30, 2016 | ||
| Related Party Transactions [Abstract] | ||
| Related Party Transactions Disclosure [Text Block] |
9. RELATED PARTY TRANSACTIONS
The Company’s former Chief Scientific Officer and principal founder of Cellectar, who resigned after the end of the fiscal period ended June 30, 2016 and continues to be a shareholder of the Company, is a faculty member at the University of Wisconsin-Madison (“UW”). During the nine months ended September 30, 2016, the Company incurred approximately $199,000 in expenses from UW for costs associated with clinical trial agreements. The Company had accrued liabilities to UW of approximately $17,000 as of September 30, 2016.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|